• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向c-MET折叠P环构象的结构基础

Structural Basis for Targeting the Folded P-Loop Conformation of c-MET.

作者信息

Collie Gavin W, Michaelides Iacovos N, Embrey Kevin, Stubbs Christopher J, Börjesson Ulf, Dale Ian L, Snijder Arjan, Barlind Louise, Song Kun, Khurana Puneet, Phillips Christopher, Storer R Ian

机构信息

Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.

Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

出版信息

ACS Med Chem Lett. 2020 Dec 8;12(1):162-167. doi: 10.1021/acsmedchemlett.0c00392. eCollection 2021 Jan 14.

DOI:10.1021/acsmedchemlett.0c00392
PMID:33488978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7812667/
Abstract

We report here a fragment screen directed toward the c-MET kinase from which we discovered a series of inhibitors able to bind to a rare conformation of the protein in which the P-loop adopts a collapsed, or folded, arrangement. Preliminary SAR exploration led to an inhibitor () with nanomolar biochemical activity against c-MET and promising cell activity and kinase selectivity. These findings increase our structural understanding of the folded P-loop conformation of c-MET and provide a sound structural and chemical basis for further investigation of this underexplored yet potentially therapeutically exploitable conformational state.

摘要

我们在此报告了一项针对c-MET激酶的片段筛选,从中发现了一系列能够结合该蛋白罕见构象的抑制剂,在这种构象中,P环呈塌陷或折叠排列。初步的构效关系探索产生了一种对c-MET具有纳摩尔生化活性、具有良好细胞活性和激酶选择性的抑制剂()。这些发现加深了我们对c-MET折叠P环构象的结构理解,并为进一步研究这种尚未充分探索但可能具有治疗开发潜力的构象状态提供了坚实的结构和化学基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/beb6/7812667/fe7f32278835/ml0c00392_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/beb6/7812667/c7348f19d335/ml0c00392_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/beb6/7812667/8dea369cc97b/ml0c00392_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/beb6/7812667/fe7f32278835/ml0c00392_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/beb6/7812667/c7348f19d335/ml0c00392_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/beb6/7812667/8dea369cc97b/ml0c00392_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/beb6/7812667/fe7f32278835/ml0c00392_0003.jpg

相似文献

1
Structural Basis for Targeting the Folded P-Loop Conformation of c-MET.靶向c-MET折叠P环构象的结构基础
ACS Med Chem Lett. 2020 Dec 8;12(1):162-167. doi: 10.1021/acsmedchemlett.0c00392. eCollection 2021 Jan 14.
2
Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.通过机制导向的结构优化发现强效的基于1H-咪唑并[4,5-b]吡啶的c-Met激酶抑制剂。
Bioorg Med Chem Lett. 2015 Feb 1;25(3):708-16. doi: 10.1016/j.bmcl.2014.11.070. Epub 2014 Dec 4.
3
Understanding the impact of the P-loop conformation on kinase selectivity.了解 P 环构象对激酶选择性的影响。
J Chem Inf Model. 2011 Jun 27;51(6):1199-204. doi: 10.1021/ci200153c. Epub 2011 May 24.
4
Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.定量构象分析揭示了激酶抑制剂对 Aurora 激酶激活态选择性的起源。
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11894-E11903. doi: 10.1073/pnas.1811158115. Epub 2018 Dec 5.
5
Targeting Conformational Activation of CDK2 Kinase.靶向细胞周期蛋白依赖性激酶2(CDK2)激酶的构象激活
Biotechnol J. 2017 Aug;12(8). doi: 10.1002/biot.201600531. Epub 2017 May 31.
6
Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.荧光标记甘氨酸丰富环作为一种识别结合激酶活性和非活性构象抑制剂的方法。
J Am Chem Soc. 2010 Mar 31;132(12):4152-60. doi: 10.1021/ja908083e.
7
Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.肺癌中 EGFR 激活环的 L858R 诱导构象变化对化疗药物反应的影响。
Mol Inform. 2016 Oct;35(10):529-537. doi: 10.1002/minf.201600088.
8
Mapping substrate-induced conformational changes in cAMP-dependent protein kinase by protein footprinting.通过蛋白质足迹法绘制环磷酸腺苷依赖性蛋白激酶中底物诱导的构象变化图谱。
Biochemistry. 1998 Oct 6;37(40):14005-13. doi: 10.1021/bi981057p.
9
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.基于结构的新型 II 型 c-Met 抑制剂设计:2. 吡唑酮系列的 SAR 和激酶选择性特征。
J Med Chem. 2012 Mar 8;55(5):1868-97. doi: 10.1021/jm201331s. Epub 2012 Feb 24.
10
Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.结肠癌中野生型和突变型BRAF激酶之间的化疗药物选择性
J Mol Model. 2017 Jan;23(1):1. doi: 10.1007/s00894-016-3177-8. Epub 2016 Dec 5.

引用本文的文献

1
E-FTMap: A Protein Structure Based Pharmacophore Identification Server for Guiding Fragment Expansion.E-FTMap:一个基于蛋白质结构的药效团识别服务器,用于指导片段扩展。
J Mol Biol. 2025 Aug 1;437(15):168956. doi: 10.1016/j.jmb.2025.168956. Epub 2025 Jan 17.
2
Discovery of -substituted-2-oxoindolin benzoylhydrazines as c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancer.在表皮生长因子受体抑制剂(EGFRi)耐药的非小细胞肺癌中发现α-取代-2-氧代吲哚苯甲酰肼作为c-MET/ smoothened(SMO)调节剂
RSC Med Chem. 2024 Oct 3. doi: 10.1039/d4md00553h.
3
Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1.

本文引用的文献

1
Properties of FDA-approved small molecule protein kinase inhibitors.已批准用于临床的小分子蛋白激酶抑制剂的特性。
Pharmacol Res. 2019 Jun;144:19-50. doi: 10.1016/j.phrs.2019.03.006. Epub 2019 Mar 13.
2
Evolution of Small Molecule Kinase Drugs.小分子激酶药物的演变
ACS Med Chem Lett. 2018 Dec 18;10(2):153-160. doi: 10.1021/acsmedchemlett.8b00445. eCollection 2019 Feb 14.
3
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.c-Met 受体酪氨酸激酶在肿瘤发生中的作用及相关治疗机会。
GNE-6893的发现,一种强效、选择性、口服生物可利用的HPK1小分子抑制剂。
ACS Med Chem Lett. 2024 Sep 3;15(9):1606-1614. doi: 10.1021/acsmedchemlett.4c00319. eCollection 2024 Sep 12.
4
The Recycling of Substandard Rocket Fuel N,N-Dimethylhydrazine via the Involvement of Its Hydrazones Derived from Glyoxal, Acrolein, Metacrolein, Crotonaldehyde, and Formaldehyde in Organic Synthesis.通过亚硝基亚甲基胍腙(由乙二醛、丙烯醛、巴豆醛、丙烯醛和甲醛衍生而来)参与有机合成,对不合格火箭燃料 N,N-二甲基肼进行回收再利用。
Int J Mol Sci. 2023 Dec 6;24(24):17196. doi: 10.3390/ijms242417196.
5
Repurposing Synthetic Congeners of a Natural Product Aurone Unveils a Lead Antitumor Agent Inhibiting Folded P-Loop Conformation of MET Receptor Tyrosine Kinase.天然产物奥洛酮合成类似物的重新利用揭示了一种抑制MET受体酪氨酸激酶折叠P环构象的先导抗肿瘤药物。
Pharmaceuticals (Basel). 2023 Nov 13;16(11):1597. doi: 10.3390/ph16111597.
6
Molecular Dynamics and Machine Learning Give Insights on the Flexibility-Activity Relationships in Tyrosine Kinome.分子动力学和机器学习在酪氨酸激酶组中的灵活性-活性关系上提供了新的见解。
J Chem Inf Model. 2023 Aug 14;63(15):4814-4826. doi: 10.1021/acs.jcim.3c00738. Epub 2023 Jul 18.
7
Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.发现并优化首个 ATP 竞争型 III 型 c-MET 抑制剂。
J Med Chem. 2023 Jul 13;66(13):8782-8807. doi: 10.1021/acs.jmedchem.3c00401. Epub 2023 Jun 21.
8
Decoding the Conformational Selective Mechanism of FGFR Isoforms: A Comparative Molecular Dynamics Simulation.解码 FGFR 同工型的构象选择性机制:比较分子动力学模拟。
Molecules. 2023 Mar 17;28(6):2709. doi: 10.3390/molecules28062709.
9
Deciphering the conformational transitions of LIMK2 active and inactive states to ponder specific druggable states through microsecond scale molecular dynamics simulation.通过微秒级别的分子动力学模拟来破译 LIMK2 活性和非活性状态的构象转变,以思考特定的可药物状态。
J Comput Aided Mol Des. 2022 Jun;36(6):459-482. doi: 10.1007/s10822-022-00459-0. Epub 2022 Jun 2.
10
Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).造血祖细胞激酶1(HPK1)的螺氮杂吲哚啉抑制剂的发现。
ACS Med Chem Lett. 2021 Dec 8;13(1):84-91. doi: 10.1021/acsmedchemlett.1c00473. eCollection 2022 Jan 13.
Mol Cancer. 2018 Feb 19;17(1):45. doi: 10.1186/s12943-018-0796-y.
4
Recent advances in the discovery of small molecule c-Met Kinase inhibitors.小分子 c-Met 激酶抑制剂发现的最新进展。
Eur J Med Chem. 2018 Jan 1;143:1103-1138. doi: 10.1016/j.ejmech.2017.08.044. Epub 2017 Aug 24.
5
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.奥希替尼与卡博替尼联合治疗一名对克唑替尼耐药后出现多个MET二次位点突变的EGFR突变型肺腺癌患者
J Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8.
6
Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations.结构表征人痘病毒相关激酶(VRK)与小分子抑制剂结合,确定不同的 P 环构象。
Sci Rep. 2017 Aug 8;7(1):7501. doi: 10.1038/s41598-017-07755-y.
7
Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.MET Y1230突变作为MET外显子14跳跃的非小细胞肺癌中克唑替尼耐药的一种获得性机制
J Thorac Oncol. 2017 Jul;12(7):e89-e90. doi: 10.1016/j.jtho.2017.02.017.
8
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.针对非小细胞肺癌中 MET 外显子 14 跳跃改变的靶点竞赛:原因、方法、人员、未知和必然。
Lung Cancer. 2017 Jan;103:27-37. doi: 10.1016/j.lungcan.2016.11.011. Epub 2016 Nov 15.
9
Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.中国携带MET外显子14剪接变异的肺腺癌患者对克唑替尼的反应及获得性耐药
Lung Cancer. 2016 Dec;102:118-121. doi: 10.1016/j.lungcan.2016.11.006. Epub 2016 Nov 9.
10
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.MET 外显子 14 跳跃型非小细胞肺癌中克唑替尼耐药的预先存在 MET Y1230C 突变的出现
J Thorac Oncol. 2017 Jan;12(1):137-140. doi: 10.1016/j.jtho.2016.09.119. Epub 2016 Sep 22.